Spartacus

Recruiting

99 years and younger

All

Phase N/A

1 Location

Brief description of study

Study is enrolling participants with IgA nephropathy to study safety and effectiveness of sparsentan in combination with SGLT2 inhibition. Participants are enrolled for 28 weeks and if taking any ACEI or ARB therapies, must discontinue prior to Day 1 visit.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 03 Sep 2024. Study ID: 855165

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Brief description of study

Eligibility of study

Find a site

What happens next?

Interested in the study